Steve Bryson, PhD,  science writer—

The first participant has been enrolled in Envision, a natural history study that will follow children with Dravet syndrome for more than two years as it seeks to shed light on how this severe type of epilepsy affects…

The use of TANGO antisense oligonucleotide-based technology, developed by Stoke Therapeutics, resulted in a dose-dependent increase in brain levels of the NaV1.1 protein that is deficient in Dravet syndrome, a mouse study has shown.  This technology can potentially treat the…

The first patient has been enrolled in Epygenix Therapeutics’ multicenter Phase 2 clinical trial that will assess the effectiveness and safety of EPX-100 as an add-on therapy in children with Dravet syndrome whose…

Fintepla (fenfluramine) oral solution, developed by Zogenix, significantly reduced seizure frequency in children and teenagers with Dravet syndrome, according to top-line results from a Phase 3 clinical trial.  This trial (Study 3)…

Activating the SCN1A gene, which is deficient in most patients with Dravet syndrome, reduced febrile seizures and improved behaviors in a mouse model, according to a recent study.  The findings support a potential new approach to treat the cause of epilepsy…

Use of cannabidiol-based Epidiolex with two anti-epileptic treatments do not appear to raise major safety concerns, with a small rise in blood concentrations of Diacomit (stiripentol) and no changes of clinical importance with Depacon (sodium valproate) seen overall in…